女性の健康の世界市場 - 2025～2032年

世界の女性の健康市場は、2024年に476億4,000万米ドルに達し、2032年には763億5,000万米ドルに達すると予測され、予測期間2025年のCAGRは5.6%で成長すると予測されています。

女性の健康は、生涯を通じて特に女性に影響を与える様々な医療・健康問題を指します。女性特有の、あるいは女性に多く見られる病気を扱い、健康の身体的側面と精神的側面の両方を包含します。

女性の健康には、避妊、性感染症（STI）、婦人科、乳がん、卵巣がんなどの女性がん、マンモグラフィなどの乳がんスクリーニング検査、更年期とホルモン療法、骨粗しょう症、妊娠・出産、性の健康、女性と心臓病、女性生殖器の機能に影響を与える良性疾患など、幅広い専門分野と重要な領域が含まれます。

市場力学：

促進要因と阻害要因

女性の意識の高まり

女性の意識の高まりが女性の健康市場を牽引すると予想されます。意識向上キャンペーンやリプロダクティブ・ヘルス（生殖に関する健康）の割合の増加により、女性の健康意識が高まっています。

女性のリプロダクティブ・ヘルス（性と生殖に関する健康）に対する意識の高まりが、女性の健康製品の需要を促進しています。例えば、2023年の世界保健機関（WHO）によると、多嚢胞性卵巣症候群（PCOS）は生殖年齢にある女性の推定8～13％が罹患しています。罹患している女性の最大70%は、世界中で未診断のままです。

女性の健康に関連する問題に対する個人の意識を高めるために、政府機関や非政府組織によって、政策への情報提供や推進、一般市民や医療専門家の教育、革新的なプログラムの支援など、幅広い活動やプログラムが実施されています。

例えば、2024年4月、クリーブランド・クリニックは、新しい女性総合健康・研究センターの立ち上げを発表しました。このセンターは、中年期以降の女性が活躍し、必要な専門的ケアを容易に受けられるよう支援することを目的としたイニシアチブです。このセンターは、アクセス、コネクティビティ、教育、研究と革新の4つの主要分野に重点を置き、女性が自信と明晰さを持って健康への道を歩んで行けるようにします。

さらに、2024年3月の国際女性デーを機に、ラマイヤ医科大学は生命・関連健康科学部傘下の構成機関と共同で、女性の健康啓発プログラムを実施しました。このように、上記のような要因が市場の成長を促進すると予想されます。

女性医療の高額なコスト

特に低所得者や十分な保険に加入していない女性は、処方箋にかかる費用が高額なため、必要不可欠な治療法に手が届かないと感じています。そのため、ホルモンバランスの乱れ、避妊、更年期症状、生殖に関する問題などの病気に必要な医薬品へのアクセスが制限されます。コストの障壁は、社会経済的に異なるグループ間におけるヘルスケアへのアクセスと転帰の格差の一因となっています。処方薬にかかる費用が高額になると、患者は推奨される治療法を部分的にしか行わなかったり、全く行わなかったりするようになります。これは、効果的な治療オプションの使用を軽視することにより、市場の成長に全体的な影響を与えます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 女性の間で高まる意識
  • 抑制要因
    • 女性医療の高額なコスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 治療の種類別

• ホルモン療法
  • エストロゲン療法
  • プロゲステロン療法
  • 併用療法
  • 甲状腺補充療法
  • その他
• 骨の健康促進剤
• 痛みと症状の管理
• 代謝剤
• 栄養補助食品
• その他

第7章 疾患適応症別

• 甲状腺疾患
• 婦人科疾患
  • 月経前緊張症
  • PCOD
  • 子宮筋腫
  • 子宮内膜症
  • その他
• がん
• 骨疾患
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Bayer AG
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Agile Therapeutics
• Amgen Inc.
• Lupin
• Sandoz AG
• Otsuka Pharmaceutical Co., Ltd.
• Nestle.
• Radius Health
• Eli Lilly and Company
• Seed Health

第11章 付録

The global Women's Health market reached US$ 47.64 billion in 2024 and is expected to reach US$ 76.35 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2025-2032.

Women's health refers to a variety of medical and health problems that impact women specifically throughout their lives. It deals with diseases that are specific to or more prevalent in women, and it encompasses both physical and emotional aspects of health.

Women's health includes a wide range of specialties and significant areas, such as birth control, sexually transmitted infections (STIs), and gynecology, breast cancer, ovarian cancer, and other female cancers, mammography and other screening tests for breast cancer, menopause and hormone therapy, osteoporosis, pregnancy and childbirth, sexual health, women and heart disease, benign conditions affecting the function of the female reproductive organs.

Market Dynamics: Drivers & Restraints

Rising awareness among women

The rising awareness among women is expected to drive the women's health market. Women are becoming more health conscious by the increasing awareness campaigns and the increasing rate of reproductive health.

With the rising incidence of deficiencies and increasing incidence of diseases among women reproductive health is increasing awareness among women which is driving the demand for women's health products. For instance, according to the World Health Organization in 2023, Polycystic ovary syndrome (PCOS) affects an estimated 8-13% of reproductive-aged women. Up to 70% of affected women remain undiagnosed worldwide.

A wide range of activities and programs that inform and advance policies, educate the public and health professionals, and support innovative programs are conducted by governmental and non-governmental organizations to promote awareness among individuals about women's health-related issues.

For instance, in April 2024, Cleveland Clinic announced the launch of its new Women's Comprehensive Health and Research Center, an initiative dedicated to helping women during midlife and beyond thrive and easily receive the specialized care they need. The center is focused on four key areas: access, connectivity, education, and research and innovation to empower women to navigate their health journey with confidence and clarity.

Additionally, in March 2024, on the occasion of International Women's Day, Ramaiah Medical College in collaboration with the constituent institutions under the Faculty of Life and Allied Health Sciences has conducted a Women's Health Awareness Program. Thus, the above factors are expected to drive the market growth.

High Costs Associated with Women's Medicine

Many women find that essential therapies are out of reach due to high prescription expenses, especially those who are low-income or lack sufficient insurance coverage. This restricts access to essential drugs for ailments like hormone imbalances, contraception, menopausal symptoms, and problems with reproductive health. Cost barriers contribute to disparities in healthcare access and outcomes among different socioeconomic groups. High prescription drug expenses can lead patients to follow recommended therapies in part or not at all. This has an overall impact on the growth of the market by neglecting the usage of effective treatment options.

Segment Analysis

The global women's health market is segmented based on treatment type, disease indication, and region.

Product:

Bone health agents segment is expected to dominate the global Women's Health share

The Bone Health Agents segment is expected to dominate the women's health market due to the increasing prevalence of bone-related health issues among women, particularly as they age. Women are at a higher risk of developing osteoporosis and other bone diseases, especially after menopause when estrogen levels decline, leading to reduced bone density. This makes bone health a critical concern for women's overall well-being. For instance, according to the Endocrine Society in 2022, Research indicates that up to 20% of bone loss can happen during these stages and approximately 1 in 10 women over the age of 60 are affected by osteoporosis worldwide.

The rising aging population, along with lifestyle factors such as poor nutrition, lack of physical activity, and smoking, is contributing to a higher incidence of bone disorders. As a result, there is a growing demand for bone health agents, including calcium and vitamin D supplements, bisphosphonates, hormone replacement therapy (HRT), and newer osteoporosis medications.

Additionally, as more women become aware of the importance of bone health, there is an increased focus on prevention, early diagnosis, and treatment of bone-related conditions. This growing awareness is driving the demand for drugs and supplements that support bone health. Thus, the above factors are expected to hold the bone health agents segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the global Women's Health share

North America is expected to hold a major position in the market share owing to the increasing awareness among individuals about rising health issues, increasing advancements in treatment options, increasing incidence of reproductive health issues and rising number of product launches.

Companies in the region are introducing solutions to support women's health. For instance, in May 2024, Solarea Bio announced the Beta Launch of Bondia, a novel daily medical food helping menopausal women manage bone loss.

Additionally, in October 2024, Nature's Bounty unveiled Nature's Bounty Intimacy Booster, Nature's Bounty Healthy pH Balance, and Nature's Bounty Hair Growth Gummies. Nature's Bounty's new products target women-specific health benefits, including hair growth and sexual and vaginal health.

The rising strategic relationships among the market players in order to expand businesses and attain the attention of the developed drugs are also expected to play a major role in rising market growth.

The increasing prevalence of reproductive health issues in the region plays a key role in the market growth. For instance, according to the Endocrine Society in 2022, it is stated that PCOS affects 7-10% of women of childbearing age and is the most common cause of infertility. In the United States, an estimated 5 to 6 million women have PCOS. Thus, the above factors are expected to hold the region in the dominant position.

Asia Pacific is at the fastest growing pace in the global Women's Health market share

Asia Pacific is currently experiencing the fastest growth in global women's health. The Asia-Pacific (APAC) region is expected to grow at the fastest pace in the women's health market due to a combination of factors. Rising awareness about women's health issues, such as reproductive health, menopause, and chronic diseases, is driving increased demand for specialized healthcare products and services. For instance, according to the Journal of the Formosan Medical Association in 2023, it stated that by 2050, more than half of all osteoporotic fractures will occur in Asia, with postmenopausal women being the most susceptible.

Competitive Landscape

The major global players in the Women's Health market include Bayer AG, Agile Therapeutics, Amgen Inc., Lupin, Sandoz AG, Otsuka Pharmaceutical Co., Ltd., Nestle., Radius Health, Eli Lilly and Company and Seed Health among others.

Key Developments

• In December 2024, Horlicks Women's Plus partnered with Apollo Diagnostics for the fourth consecutive year to address women's bone health in India. This collaboration aims to raise awareness about Vitamin D deficiency, which impacts bone health and increases the risk of conditions such as osteoporosis.
• In March 2024, Sandoz, received the US Food and Drug Administration (FDA) approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines. Jubbonti is approved to treat postmenopausal women with osteoporosis at high risk for fracture.
• In September 2024, Otsuka Pharmaceutical Co., Ltd. announced the U.S. launch of "Thermella(TM)", a plant-based supplement that contributes to women's health during menopause.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Women's Health Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Disease Indication
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising awareness among women
  • 4.1.2. Restraints
    • 4.1.2.1. High Costs Associated with Women's Medicine
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Hormonal Therapy*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Estrogen Therapy
  • 6.2.4. Progesterone Therapy
  • 6.2.5. Combination Therapy
  • 6.2.6. Thyroid Replacement Therapy
  • 6.2.7. Others
• 6.3. Bone Health Agents
• 6.4. Pain and Symptom Management
• 6.5. Metabolic Agents
• 6.6. Nutrition Supplements
• 6.7. Others

7. By Disease Indication

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 7.1.2. Market Attractiveness Index, By Disease Indication
• 7.2. Thyroid Disorders*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Gynecological Disorders
  • 7.3.1. PMS
  • 7.3.2. PCOD
  • 7.3.3. Uterine Fibroids
  • 7.3.4. Endometriosis
  • 7.3.5. Others
• 7.4. Cancer
• 7.5. Bone Disorders
• 7.6. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Bayer AG*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
• 10.2. Agile Therapeutics
• 10.3. Amgen Inc.
• 10.4. Lupin
• 10.5. Sandoz AG
• 10.6. Otsuka Pharmaceutical Co., Ltd.
• 10.7. Nestle.
• 10.8. Radius Health
• 10.9. Eli Lilly and Company
• 10.10. Seed Health

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us